Loading clinical trials...
Loading clinical trials...
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects
Conditions
Interventions
PRO 140
Placebo
+1 more
Locations
36
United States
CD02 Investigational site
Fountain Valley, California, United States
CD02 Investigational site
Long Beach, California, United States
CD02 Investigational site
Los Angeles, California, United States
CD02 Investigational Site
Los Angeles, California, United States
CD02 Investigational site
Palm Springs, California, United States
CD02 Investigational Site
San Francisco, California, United States
Start Date
October 1, 2015
Primary Completion Date
February 1, 2018
Completion Date
July 1, 2018
Last Updated
November 3, 2022
NCT01875588
NCT06598397
NCT06857071
NCT06627764
NCT07509853
NCT05384145
Lead Sponsor
CytoDyn, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions